Clinical Trials Logo
  1. Home
  2. Acute Heart Failure
  3. NCT05986773

Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance — P-Value-AHF  

Acute Heart Failure Clinical Trial

Official title:
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance (P-Value-AHF): A Multicentre, Randomized, Parallel-group, Open-label Trial

Clinical Trial Summary

The P-VALUE-AHF trial is a multicenter, randomized, open-label, parallel-group trial on the diuretic and decongestive effects of different diuretic escalation strategies in patients with acute heart failure and diuretic resistance. The main aims are - to compare the diuretic efficacy of three therapeutic strategies in patients with acute heart failure and diuretic resistance. - to assess the improvement in clinical congestion and to compare the symptom-relief among the different treatment regimens

Clinical Trial Description

The P-VALUE-AHF trial is a multicenter, randomized, open-label, parallel-group trial on the diuretic and decongestive effects of different diuretic escalation strategies in patients with acute heart failure (AHF) and diuretic resistance (DR). Consenting patients with AHF and DR will be will be randomized towards 3 diuretic regimens. Two to five hours after the initial standard dose Furosemide i.v, - the first group will receive a doubled dose Furosemide (group FF) - the second group will receive a combination of standard dose Furosemide and Metolazone (group FM) - the third group will receive a combination of standard dose Furosemide and Acetazolamide (group FA) Objectives - The primary objective is to compare the diuretic efficacy (measured as natriuresis and urine volume) of three therapeutic strategies in patients with acute heart failure and diuretic resistance. - The secondary objective is to assess the improvement in clinical congestion (EVEREST congestion score) and to compare the symptom-relief (improvement of dyspnoea (VAS)) among the different treatment regimens (FF vs. FM vs. FA). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05986773
Study type Interventional
Source Stadtspital Zürich
Contact Mattia Arrigo, PD, Dr. med.
Phone +41 44 416 30 03
Email mattia.arrigo@stadtspital.ch
Status Recruiting
Phase Phase 4
Start date October 10, 2023
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02151383 - Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure Phase 2
Completed NCT02135835 - A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure Phase 4
Recruiting NCT05556044 - Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction Phase 3
Recruiting NCT04363697 - Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Phase 4
Completed NCT02122640 - Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department N/A
Completed NCT01193998 - Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department N/A
Not yet recruiting NCT01211886 - Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU) N/A
Not yet recruiting NCT06465498 - Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography N/A
Recruiting NCT05276219 - Optimized Treatment of Pulmonary Edema or Congestion Phase 4
Recruiting NCT05392764 - Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure Phase 3
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Completed NCT06024889 - Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure. Phase 1/Phase 2
Terminated NCT04174794 - Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
Recruiting NCT05972746 - Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure N/A
Enrolling by invitation NCT02258984 - Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial N/A
Completed NCT02141607 - Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
Completed NCT01870778 - Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF Phase 3
Recruiting NCT04163588 - Sequential Nephron Blockade in Acute Heart Failure Phase 3
Recruiting NCT03717636 - Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure N/A
Recruiting NCT04329234 - Korean Heart Failure Registry III